Ontario Teachers Pension Plan Board Purchases Shares of 1,482 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ontario Teachers Pension Plan Board acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, HoldingsChannel reports. The institutional investor acquired 1,482 shares of the company’s stock, valued at approximately $749,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Horizon Advisors Inc. lifted its holdings in IDEXX Laboratories by 4.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 704 shares of the company’s stock worth $356,000 after purchasing an additional 27 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of IDEXX Laboratories by 4.2% in the third quarter. Advisors Asset Management Inc. now owns 3,265 shares of the company’s stock worth $1,650,000 after buying an additional 131 shares in the last quarter. NS Partners Ltd grew its stake in IDEXX Laboratories by 2.0% during the third quarter. NS Partners Ltd now owns 39,310 shares of the company’s stock valued at $19,860,000 after acquiring an additional 761 shares in the last quarter. Prospera Private Wealth LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $157,000. Finally, PNC Financial Services Group Inc. lifted its stake in IDEXX Laboratories by 0.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 40,300 shares of the company’s stock worth $20,360,000 after purchasing an additional 184 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on IDXX shares. Piper Sandler restated a “neutral” rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. BTIG Research started coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. JPMorgan Chase & Co. lowered their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Finally, Barclays lowered their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Trading Up 0.2 %

IDXX stock opened at $419.37 on Friday. The firm’s fifty day simple moving average is $462.53 and its two-hundred day simple moving average is $481.11. The stock has a market capitalization of $34.34 billion, a price-to-earnings ratio of 40.44, a price-to-earnings-growth ratio of 3.63 and a beta of 1.36. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same period in the prior year, the company posted $2.53 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.